Login Register Cart 0
Research Article

Popularizing Recombinant Baculovirus-derived OneBac System for Laboratory Production of all Recombinant Adeno-associated Virus Vector Serotypes

Author(s): Yang Wu*, Zengpeng Han, Mingzhu Duan, Liangyu Jiang, Tiantian Tian, Dingyu Jin, Qitian Wang and Fuqiang Xu*

Volume 21, Issue 2, 2021

Published on: 18 January, 2021

Page: [167 - 176] Pages: 10

DOI: 10.2174/1566523221666210118111657

Price: $65

Abstract

Background: Recombinant adeno-associated virus (rAAV) has been widely used as an efficient transgenic vector in biomedical research, as well as gene therapy. Serotype-associated transduction efficiency, tissue- or cell-type tropism and immunological profile are major considerations in the various applications of rAAVs. There are increasing needs for different serotypes of rAAV, either naturally isolated or artificially engineered. However, affordable and scalable production of a desired serotype of rAAV remains very difficult, especially for researchers lacking relevant experience.

Objective: On the basis of our previously established single recombinant baculovirus expression vector (BEV)-derived OneBac system, we have optimized the process and expanded the rAAV production range to the full range of serotypes rAAV1-13.

Methods: Firstly, the AAV Cap gene was optimized to translate by ribosome leaky scanning and the gene of interest (GOI) was cloned into the pFD/Cap-(ITR-GOI)-Rep2 shuttle plasmid. Following the classical Bac-to-Bac method, sufficient BEV stock containing all rAAV packaging elements can be quickly obtained. Finally, we can repeatedly scale up the production of rAAVs in one week by using a single BEV to infect suspension-cultured Sf9 cells. The rAAV1-13 shows relatively high yields ranging from 5×104 to 4×105 VG/cell. More than 1×1015 VG purified rAAVs can be easily obtained from 5 L suspension-cultured Sf9 cells.

Results: As expected, rAAV serotypes 1-13 show different potencies for in vitro transduction and cell-type tropisms.

Conclusion: In summary, the single BEV-derived OneBac system should prove popular for laboratory scaling-up production of any serotype of rAAV.

Keywords: rAAV, recombinant baculovirus, OneBac system, scaling-up production, serotype, gene therapy.

« Previous Next »
Graphical Abstract

[1]
Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008; 21(4): 583-93.
[http://dx.doi.org/10.1128/CMR.00008-08] [PMID: 18854481]
[2]
Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov 2019; 18(5): 358-78.
[http://dx.doi.org/10.1038/s41573-019-0012-9] [PMID: 30710128]
[3]
Wang D, Zhang F, Gao G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by aav vectors. Cell 2020; 181(1): 136-50.
[http://dx.doi.org/10.1016/j.cell.2020.03.023] [PMID: 32243786]
[4]
Haggerty DL, Grecco GG, Reeves KC, Atwood B. Adeno-Associated Viral Vectors in Neuroscience Research. Mol Ther Methods Clin Dev 2019; 17: 69-82.
[http://dx.doi.org/10.1016/j.omtm.2019.11.012] [PMID: 31890742]
[5]
Domenger C, Grimm D. Next-generation AAV vectors-do not judge a virus (only) by its cover. Hum Mol Genet 2019; 28(R1): R3-R14.
[http://dx.doi.org/10.1093/hmg/ddz148] [PMID: 31261383]
[6]
Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther 2005; 5(3): 285-97.
[http://dx.doi.org/10.2174/1566523054065057] [PMID: 15975006]
[7]
Mietzsch M, Broecker F, Reinhardt A, Seeberger PH, Heilbronn R. Differential adeno-associated virus serotype-specific interaction patterns with synthetic heparins and other glycans. J Virol 2014; 88(5): 2991-3003.
[http://dx.doi.org/10.1128/JVI.03371-13] [PMID: 24371066]
[8]
Mary B, Khan N, Arumugam S, et al. Adeno-associated Virus Vectors in Gene Therapy Gene and Cell Therapy: Biology and Applications. Springer Singapore 2018; pp. 29-56.
[9]
Büning H, Huber A, Zhang L, Meumann N, Hacker U. Engineering the AAV capsid to optimize vector-host-interactions. Curr Opin Pharmacol 2015; 24: 94-104.
[http://dx.doi.org/10.1016/j.coph.2015.08.002] [PMID: 26302254]
[10]
Grimm D, Zolotukhin S. E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution. Mol Ther 2015; 23(12): 1819-31.
[http://dx.doi.org/10.1038/mt.2015.173] [PMID: 26388463]
[11]
Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet 2020; 21(4): 255-72.
[http://dx.doi.org/10.1038/s41576-019-0205-4] [PMID: 32042148]
[12]
Tse LV, Klinc KA, Madigan VJ, et al. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proc Natl Acad Sci USA 2017; 114(24): e4812-21.
[http://dx.doi.org/10.1073/pnas.1704766114] [PMID: 28559317]
[13]
Deverman BE, Pravdo PL, Simpson BP, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol 2016; 34(2): 204-9.
[http://dx.doi.org/10.1038/nbt.3440] [PMID: 26829320]
[14]
Watakabe A, Ohtsuka M, Kinoshita M, et al. Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex. Neurosci Res 2014; 9: 18.
[PMID: 25240284]
[15]
Aschauer DF, Kreuz S, Rumpel S. Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS One 2013; 8(9)e76310
[http://dx.doi.org/10.1371/journal.pone.0076310] [PMID: 24086725]
[16]
Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008; 16(6): 1073-80.
[http://dx.doi.org/10.1038/mt.2008.76] [PMID: 18414476]
[17]
Grimm D, Lee JS, Wang L, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol 2008; 82(12): 5887-911.
[http://dx.doi.org/10.1128/JVI.00254-08] [PMID: 18400866]
[18]
Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA 1984; 81(20): 6466-70.
[http://dx.doi.org/10.1073/pnas.81.20.6466] [PMID: 6093102]
[19]
Ayuso E, Mingozzi F, Bosch F. Production, purification and characterization of adeno-associated vectors. Curr Gene Ther 2010; 10(6): 423-36.
[http://dx.doi.org/10.2174/156652310793797685] [PMID: 21054248]
[20]
Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72(3): 2224-32.
[http://dx.doi.org/10.1128/JVI.72.3.2224-2232.1998] [PMID: 9499080]
[21]
Chahal PS, Schulze E, Tran R, Montes J, Kamen AA. Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery. J Virol Methods 2014; 196: 163-73.
[http://dx.doi.org/10.1016/j.jviromet.2013.10.038] [PMID: 24239634]
[22]
Grieger JC, Soltys SM, Samulski RJ. Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. Mol Ther 2016; 24(2): 287-97.
[http://dx.doi.org/10.1038/mt.2015.187] [PMID: 26437810]
[23]
Rabinowitz JE, Rolling F, Li C, et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76(2): 791-801.
[http://dx.doi.org/10.1128/JVI.76.2.791-801.2002] [PMID: 11752169]
[24]
Ye C, Qiu J, Pintel DJ. Efficient expression of the adeno-associated virus type 5 p41 capsid gene promoter in 293 cells does not require Rep. J Virol 2006; 80(13): 6559-67.
[http://dx.doi.org/10.1128/JVI.00387-06] [PMID: 16775342]
[25]
Emmerling VV, Pegel A, Milian EG, et al. Rational plasmid design and bioprocess optimization to enhance recombinant adeno-associated virus (AAV) productivity in mammalian cells. Biotechnol J 2016; 11(2): 290-7.
[http://dx.doi.org/10.1002/biot.201500176] [PMID: 26284700]
[26]
Van der Loo JC, Wright JF. Progress and challenges in viral vector manufacturing. Hum Mol Genet 2016; 25(R1): R42-52.
[http://dx.doi.org/10.1093/hmg/ddv451] [PMID: 26519140]
[27]
O’Connor DM, Lutomski C, Jarrold MF, Boulis NM, Donsante A. Lot-to-Lot variation in Adeno-Associated virus serotype 9 (AAV9) preparations. Hum Gene Ther Methods 2019; 30(6): 214-25.
[http://dx.doi.org/10.1089/hgtb.2019.105] [PMID: 31752530]
[28]
Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 2002; 13(16): 1935-43.
[http://dx.doi.org/10.1089/10430340260355347] [PMID: 12427305]
[29]
Chen H. Intron splicing-mediated expression of AAV Rep and Cap genes and production of AAV vectors in insect cells. Mol Ther 2008; 16(5): 924-30.
[http://dx.doi.org/10.1038/mt.2008.35] [PMID: 18388928]
[30]
Smith RH, Levy JR, Kotin RM. A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther 2009; 17(11): 1888-96.
[http://dx.doi.org/10.1038/mt.2009.128] [PMID: 19532142]
[31]
Aslanidi G, Lamb K, Zolotukhin S. An inducible system for highly efficient production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells. Proc Natl Acad Sci USA 2009; 106(13): 5059-64.
[http://dx.doi.org/10.1073/pnas.0810614106] [PMID: 19279219]
[32]
Mietzsch M, Grasse S, Zurawski C, et al. OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy. Hum Gene Ther 2014; 25(3): 212-22.
[http://dx.doi.org/10.1089/hum.2013.184] [PMID: 24299301]
[33]
Wu Y, Mei T, Jiang L, et al. Development of Versatile and Flexible Sf9 Packaging Cell Line-Dependent OneBac System for Large-Scale Recombinant Adeno-Associated Virus Production. Hum Gene Ther Methods 2019; 30(5): 172-83.
[http://dx.doi.org/10.1089/hgtb.2019.123] [PMID: 31566024]
[34]
Wu Y, Jiang L, Geng H, et al. A Recombinant Baculovirus Efficiently Generates Recombinant Adeno-Associated Virus Vectors in Cultured Insect Cells and Larvae. Mol Ther Methods Clin Dev 2018; 10: 38-47.
[http://dx.doi.org/10.1016/j.omtm.2018.05.005] [PMID: 29988889]
[35]
Zolotukhin S, Byrne BJ, Mason E, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999; 6(6): 973-85.
[http://dx.doi.org/10.1038/sj.gt.3300938] [PMID: 10455399]
[36]
Strobel B, Miller FD, Rist W, Lamla T. Comparative analysis of cesium chloride- and iodixanol-based purification of recombinant adeno-associated viral vectors for preclinical applications. Hum Gene Ther Methods 2015; 26(4): 147-57.
[http://dx.doi.org/10.1089/hgtb.2015.051] [PMID: 26222983]
[37]
Zuchero JB, Barres BA. Glia in mammalian development and disease. Development 2015; 142(22): 3805-9.
[http://dx.doi.org/10.1242/dev.129304] [PMID: 26577203]
[38]
Maes ME, Colombo G, Schulz R, Siegert S. Targeting microglia with lentivirus and AAV: Recent advances and remaining challenges. Neurosci Lett 2019; 707134310
[http://dx.doi.org/10.1016/j.neulet.2019.134310] [PMID: 31158432]
[39]
Kost TA, Condreay JP, Jarvis DL. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol 2005; 23(5): 567-75.
[http://dx.doi.org/10.1038/nbt1095] [PMID: 15877075]
[40]
Mietzsch M, Casteleyn V, Weger S, Zolotukhin S, Heilbronn R. OneBac 2.0: Sf9 Cell Lines for Production of AAV5 Vectors with Enhanced Infectivity and Minimal Encapsidation of Foreign DNA. Hum Gene Ther 2015; 26(10): 688-97.
[http://dx.doi.org/10.1089/hum.2015.050] [PMID: 26134901]
[41]
Girod A, Wobus CE, Zadori Z, et al. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol 2002; 83(5): 973-8.
[http://dx.doi.org/10.1099/0022-1317-83-5-973]
[42]
Kondratov O, Marsic D, Crosson SM, et al. Direct Head-to-Head Evaluation of Recombinant Adeno-associated Viral Vectors Manufactured in Human versus Insect Cells. Mol Ther 2017; 25(12): 2661-75.
[http://dx.doi.org/10.1016/j.ymthe.2017.08.003] [PMID: 28890324]

Rights & Permissions Print Cite
Article Metrics
32
1
© 2024 Bentham Science Publishers | Privacy Policy